A phase 3 trial found that Eli Lilly's tirzepatide ... with an average body weight reduction of up to 23% with the highest dose, according to a Nov. 13 news release from the drugmaker. In addition to ...

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Tirzepatide is undergoing several other studies. Further, Eli Lilly's pipeline features other promising candidates, ...

At the 15mg dose, participants showed a sustained average weight loss of 22.9% during the three-year treatment. Credit: SB ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

But Matt Phipps, a William Blair analyst, noted that significant weight loss is often tied to declining bone mineral ... GIPR is involved in insulin release and glycemic control. Rival drugs from Eli ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Amgen is testing MariTide as a once-monthly shot, making it a promising potential rival to the weekly blockbuster weight-loss injections from Novo Nordisk and Eli Lilly. Tuesday's stock decline lopped ...